Anbio Biotechnology (NNNN) Receivables (2023 - 2025)

Anbio Biotechnology has reported Receivables for 3 years, with the latest figure at $3.7 million in Q4 2025.

• On a quarterly basis, Receivables rose 243.44% year-over-year to $3.7 million in Q4 2025; TTM through Dec 2025 was $3.7 million, a 243.44% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, up 243.44% from the prior year.
• Receivables was $3.7 million for Q4 2025 at Anbio Biotechnology, down from $3.7 million in the prior quarter.
• The five-year high for Receivables was $3.7 million in Q2 2025, with the low at $1.1 million in Q4 2024.
• Average Receivables over 3 years is $2.6 million, with a median of $2.8 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables tumbled 43.51% in 2024, then jumped 243.44% in 2025.
• Over 3 years, Receivables stood at $1.9 million in 2023, then plunged by 43.51% to $1.1 million in 2024, then surged by 243.44% to $3.7 million in 2025.
• The last three Receivables figures came in at $3.7 million (Q4 2025), $3.7 million (Q2 2025), and $1.1 million (Q4 2024), per Business Quant data.